Peptide Modulation Overrides Glycan Synergy in Gold Nanoparticle‐Based Vaccines for Cancer Immunotherapy
Cancer Medicine · 2025
DOI: 10.1002/cam4.71286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Narumi Harada und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Gold, Metal Nanoparticles, Cancer Vaccines, Immunotherapy. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Takeda Science Foundation.
Abstract (Originalsprache)
Background
We have previously developed a gold nanoparticle (GNP)‐based anti‐cancer immunotherapy, termed integrated glyco‐nanovaccine (iGN). The iGN is composed of GNPs conjugated to a synthetic toll‐like receptor (TLR) 7 ligand, an antigen peptide, and a mannose sugar chain. However, the effect of the combination of different sugar chains and antigen peptides on iGN‐mediated anticancer immunotherapy remains to be elucidated.
Objective
We compared the anti‐tumor effects of two different sugar chains: α‐mannose and sialic acid.
Results
We showed that not only the sugar chain but also the antigen peptide plays a pivotal role in iGN uptake by immune cells. In contrast to α‐mannose, which promoted GNP internalization by bone marrow‐derived dendritic cells (BMDC), sialic acid modification resulted in limited cellular uptake. The integration of major histocompatibility complex class I‐restricted ovalbumin peptides drastically changed this cellular recognition pattern, particularly for sialic acid‐modified iGN. The peptide largely improved the uptake of nanoparticles, delivery of the TLR 7 ligand, and subsequent activation of the type I interferon pathway in BMDC. Sialic acid‐modified iGN demonstrated comparable induction of CD8 + T cell and efficacy of anti‐cancer therapy to α‐mannose‐modified iGN in an EG7 syngeneic mouse tumor model.
Conclusions
These results indicate that antigens, and not only the sugar chain, critically determine both the cellular internalization and immunotherapeutic efficacy of iGNs. This study presents a new design principle for glyco‐nanovaccines, where peptides override glycan synergy and determine therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Division of Cellular Dynamics, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan.
- Department of Engineering, Chemistry and Biotechnology Program, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
- Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
ORCID-Profile: Narumi Harada, Toshiro Moroishi
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Takeda Science Foundation
- Japan Science and Technology Agency
- Hoansha Foundation
Zitieren
APA
Harada, N., Niimura, M., Sakamoto, Y., Nita, A., Shimoda, M., Wada, S., Murata, K., Wakao, M., Kamba, T., Shinchi, H., & Moroishi, T. (2025). Peptide Modulation Overrides Glycan Synergy in Gold Nanoparticle‐Based Vaccines for Cancer Immunotherapy. Cancer Medicine. https://doi.org/10.1002/cam4.71286
Vancouver
Harada N, Niimura M, Sakamoto Y, Nita A, Shimoda M, Wada S, et al. Peptide Modulation Overrides Glycan Synergy in Gold Nanoparticle‐Based Vaccines for Cancer Immunotherapy. Cancer Medicine. 2025. doi:10.1002/cam4.71286
BibTeX
@article{Harada2025,
author = {Harada, Narumi and Niimura, Mayumi and Sakamoto, Yasuhisa and Nita, Akihiro and Shimoda, Mayuko and Wada, Shiho and Murata, Koki and Wakao, Masahiro and Kamba, Tomomi and Shinchi, Hiroyuki and Moroishi, Toshiro},
title = {Peptide Modulation Overrides Glycan Synergy in Gold Nanoparticle‐Based Vaccines for Cancer Immunotherapy},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71286}
}
EUVIMED